Somatic mutations in the CRLF2 gene mediated via juxtaposition to the immunoglobulin heavy chain gene (IGH) transcriptional enhancers are present in 7% of B-ALL cases [7] and 50% of DS-ALL patients [8]. The gene discussed is CRLF2; the disease is precursor B-cell acute lymphoblastic leukemia.